Denmark: A recent study published in The Journal of Clinical Endocrinology and Metabolism has shed light on the effects of exogenous glucose-dependent insulinotropic polypeptide (GIP) and.
Spain: Liraglutide may increase forced vital capacity (FVC) in type 2 diabetes patients, finds a recent study. This effect was shown to be linked to a significant decrease in circulating serum levels.